Kazazian Asset Management LLC Purchases Shares of 42,036 MacroGenics, Inc. (NASDAQ:MGNX)

Kazazian Asset Management LLC purchased a new stake in MacroGenics, Inc. (NASDAQ:MGNX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 42,036 shares of the biopharmaceutical company’s stock, valued at approximately $137,000. Kazazian Asset Management LLC owned about 0.07% of MacroGenics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in MacroGenics in the third quarter valued at $37,000. Sanders Morris Harris LLC purchased a new stake in MacroGenics in the fourth quarter valued at $40,000. Intech Investment Management LLC purchased a new stake in MacroGenics in the third quarter valued at $68,000. XML Financial LLC boosted its holdings in MacroGenics by 31.6% in the fourth quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 5,569 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in MacroGenics by 104.5% in the fourth quarter. SG Americas Securities LLC now owns 34,399 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 17,577 shares during the last quarter. 96.89% of the stock is owned by hedge funds and other institutional investors.

MacroGenics Stock Performance

NASDAQ:MGNX opened at $2.05 on Wednesday. The firm’s fifty day moving average is $2.73 and its two-hundred day moving average is $3.24. MacroGenics, Inc. has a one year low of $2.04 and a one year high of $19.54. The firm has a market cap of $128.66 million, a price-to-earnings ratio of -1.30 and a beta of 2.12.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.